Table 1. Treatment-related Grade 2-4 adverse events.

	Dose Level	1 n=2	2 n=1	3 n=0	4 n=1	5 n=0	6 n=0	7 n=3	8 n=34	Total n=41
	Bevacizumab Dose, mg/kg IV q2w	2.5	5	5	5	7.5	7.5	7.5	10
	Cetuximab Dose, mg/m2 IV weekly*	100, 75	100, 75	200, 125	200, 125	200, 125	400, 250	400, 250	400, 250
	Erlotinib Dose, mg po daily	50	50	50	100	100	100	150	150
Skin rash
Grade 2		0	0	0	1	0	0	2	16	19 (46%)
Grade 3		0	0	0	0	0	0	1	8	9 (22%)
Hypomagnesemia
Grade 2		0	0	0	0	0	0	0	11	11 (27%)
Grade 3		0	0	0	0	0	0	1	3	4 (10%)
Grade 4		0	0	0	1	0	0	0	2	3 (7%)
Fatigue
Grade 2		0	0	0	0	0	0	0	5	5 (12%)
Grade 3		0	0	0	0	0	0	0	1	1 (2%)
Diarrhea
Grade 2		0	0	0	0	0	0	0	3	3 (7%)
Grade 3		0	0	0	0	0	0	1	1	2 (5%)
Hyperbilirubemia
Grade 2		0	0	0	0	0	0	0	3	3 (7%)
Grade 3		0	0	0	0	0	0	1	0	1 (2%)
Thrombocytopenia
Grade 2		0	0	0	1	0	0	0	1	2 (5%)
Grade 3a		0	0	0	0	0	0	0	1	1 (2%)
Anorexia
Grade 2		0	0	0	0	0	0	0	2	2 (5%)
Fever and chills
Grade 2		0	0	0	0	0	0	0	2	2 (5%)
Hypertension
Grade 2		0	0	0	0	0	0	0	2	2 (5%)
Chest pain
Grade 3		0	0	0	0	0	0	1	0	1 (2%)
Chills
Grade 2		0	0	0	0	0	0	0	1	1 (2%)
Constipation
Grade 2		0	0	0	0	0	0	0	1	1 (2%)
Dyspnea
Grade 3		0	0	0	0	0	0	1	0	1 (2%)
Fistula
Grade 3		0	0	0	0	0	0	0	1	1 (2%)
Hand and foot syndrome
Grade 2		0	0	0	1	0	0	0	0	1 (2%)
Increased AST
Grade 2		0	0	0	0	0	0	0	1	1 (2%)
Increased AST/ALT
Grade 2		0	0	0	0	0	0	1	0	1 (2%)
Infusion reaction
Grade 3		0	0	0	0	0	0	1	0	1 (2%)
Neutropenia
Grade 3		0	0	0	0	0	0	0	1	1 (2%)
Proteinuria
Grade 2		0	0	0	0	0	0	0	1	1 (2%)
Pruritis
Grade 3		0	0	0	0	0	0	0	1	1 (2%)

Abbreviations: DLT, dose-limiting toxicity; IV, intravenous; po, orally

^†Recommended Phase II dose.³¹ This includes full approved doses of each drug.

^*Cetuximab dose shown as loading dose, maintenance dose.